{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T22:57:33Z","timestamp":1795215453613,"version":"4.10.3"},"reference-count":151,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To systematically review the literature and provide clinical practice guidelines regarding various nonestrogen therapies for treatment of genitourinary syndrome of menopause (GSM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>MEDLINE, EMBASE, ClinicalTrials.gov, and Cochrane databases were searched from inception to July 2021. We included comparative and noncomparative studies. Interventions and comparators were limited to seven products that are commercially available and currently in use (vaginal dehydroepiandrosterone [DHEA], ospemifene, laser or energy-based therapies, polycarbophil-based vaginal moisturizer, Tibolone, vaginal hyaluronic acid, testosterone). Topical estrogen, placebo, other nonestrogen products, as well as no treatment were considered as comparators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS OF STUDY SELECTION:<\/jats:title>\n                    <jats:p>We double-screened 9,131 abstracts and identified 136 studies that met our criteria. Studies were assessed for quality and strength of evidence by the systematic review group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n                    <jats:p>\n                      Information regarding the participants, details on the intervention and comparator and outcomes were extracted from the eligible studies. Alternative therapies were similar or superior to estrogen or placebo with minimal increase in adverse events. Dose response was noted with vaginal DHEA and testosterone. Vaginal DHEA, ospemifene, erbium and fractional carbon dioxide (CO\n                      <jats:sub>2<\/jats:sub>\n                      ) laser, polycarbophil-based vaginal moisturizer, tibolone, hyaluronic acid, and testosterone all improved subjective and objective signs of atrophy. Vaginal DHEA, ospemifene, tibolone, fractional CO\n                      <jats:sub>2<\/jats:sub>\n                      laser, polycarbophil-based vaginal moisturizer, and testosterone improved sexual function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Most nonestrogen therapies are effective treatments for the various symptoms of GSM. There are insufficient data to compare nonestrogen options to each other.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005288","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T02:08:05Z","timestamp":1691287685000},"page":"555-570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause"],"prefix":"10.1097","volume":"142","author":[{"given":"Elizabeth A.","family":"Casiano Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deslyn T. G.","family":"Hobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit O.","family":"Aschkenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandriah N.","family":"Alas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Balgobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan M.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis A.","family":"Dieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Orejuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V. D.","family":"Sanses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Rahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clinic Proc"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/IJWH.S44579","article-title":"Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy","volume":"5","author":"Parish","year":"2013","journal-title":"Int J Womens Health"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/AOG.0000000000000526","article-title":"Vaginal estrogen for genitourinary syndrome of menopause: a systematic review","volume":"124","author":"Rahn","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R4-20260916","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001500.pub3","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","author":"Lethaby","year":"2016","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health","volume":"25","author":"Faubion","year":"2018","journal-title":"Menopause"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/GME.0000000000001049","article-title":"Vulvar and vaginal fractional CO2 laser treatments for genitourinary syndrome of menopause","volume":"25","author":"Streicher","year":"2018","journal-title":"Menopause"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2105-11-55","article-title":"Semi-automated screening of biomedical citations for systematic reviews","volume":"11","author":"Wallace","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jclinepi.2009.03.009","article-title":"AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions\u2014agency for healthcare research and quality and the effective health-care program","volume":"63","author":"Owens","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/GME.0000000000000428","article-title":"Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)","volume":"22","author":"Archer","year":"2015","journal-title":"Menopause"},{"key":"R11-20260916","first-page":"1335","article-title":"Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"R12-20260916","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/gme.0b013e31819e85c6","article-title":"Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/gme.0b013e31819e8e2d","article-title":"Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/13697137.2010.535226","article-title":"Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia","volume":"14","author":"Labrie","year":"2011","journal-title":"Climacteric"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000000571","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"23","author":"Labrie","year":"2016","journal-title":"Menopause"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/jsm.13045","article-title":"Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy","volume":"12","author":"Labrie","year":"2015","journal-title":"J Sex Med"},{"key":"R18-20260916","first-page":"181","article-title":"Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study","volume":"25","author":"Bouchard","year":"2016","journal-title":"Horm Mol Biol Clin Invest"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.maturitas.2015.02.005","article-title":"Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study","volume":"81","author":"Labrie","year":"2015","journal-title":"Maturitas"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1210\/jcem.82.10.4306","article-title":"Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women","volume":"82","author":"Labrie","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejogrb.2021.06.009","article-title":"Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: a pilot study","volume":"263","author":"Matarazzo","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.jsxm.2018.10.009","article-title":"Structure of epithelial and stromal compartments of vulvar and vaginal tissue from women with vulvo-vaginal atrophy taking ospemifene","volume":"15","author":"Alvisi","year":"2018","journal-title":"J Sex Med"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/09513590.2017.1332589","article-title":"Effects of ospemifene on vaginal epithelium of post-menopausal women","volume":"33","author":"Alvisi","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"R24-20260916","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/GME.0000000000001292","article-title":"Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial","volume":"26","author":"Archer","year":"2019","journal-title":"Menopause"},{"key":"R25-20260916","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"R26-20260916","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","article-title":"Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial","volume":"18","author":"Constantine","year":"2015","journal-title":"Climacteric"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/GME.0000000000001350","article-title":"Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal\/vulvar health indices","volume":"26","author":"Goldstein","year":"2019","journal-title":"Menopause"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climacteric"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"R32-20260916","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/jwh.2017.6385","article-title":"Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials","volume":"27","author":"Simon","year":"2018","journal-title":"J Womens Health"},{"key":"R33-20260916","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.esxm.2018.03.002","article-title":"Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study","volume":"6","author":"Goldstein","year":"2018","journal-title":"Sex Med"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/09513590.2018.1427717","article-title":"Vulvar vestibular effects of ospemifene: a pilot study","volume":"34","author":"Murina","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.maturitas.2020.05.001","article-title":"Potential effectiveness of ospemifene on detrusor overactivity in patients with vaginal atrophy","volume":"138","author":"Novara","year":"2020","journal-title":"Maturitas"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/09513590.2020.1853695","article-title":"Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use","volume":"37","author":"Pingarron","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/09513590.2017.1370645","article-title":"Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene","volume":"34","author":"Schiavi","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/09513590.2018.1441398","article-title":"Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?","volume":"34","author":"Schiavi","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1080\/09513590.2017.1323859","article-title":"Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms","volume":"33","author":"Schiavi","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.maturitas.2013.12.005","article-title":"Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women","volume":"77","author":"Simon","year":"2014","journal-title":"Maturitas"},{"key":"R43-20260916","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/lsm.23220","article-title":"Efficacy of fractional CO2 laser, promestriene, and vaginal lubricant in the treatment of urinary symptoms in postmenopausal women: a randomized clinical trial","volume":"52","author":"Aguiar","year":"2020","journal-title":"Lasers Surg Med"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jsxm.2021.01.188","article-title":"A double-blind randomized sham-controlled trial to evaluate the efficacy of fractional carbon dioxide laser therapy on genitourinary syndrome of menopause","volume":"18","author":"Cruff","year":"2021","journal-title":"J Sex Med"},{"key":"R45-20260916","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GME.0000000000000955","article-title":"Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women","volume":"25","author":"Cruz","year":"2018","journal-title":"Menopause"},{"key":"R46-20260916","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/GME.0000000000001797","article-title":"Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial","volume":"28","author":"Dutra","year":"2021","journal-title":"Menopause"},{"key":"R47-20260916","doi-asserted-by":"crossref","first-page":"292","DOI":"10.34172\/jlms.2020.49","article-title":"The effect of the CO2 fractional laser or premarin vaginal cream on improving sexual function in menopausal women: a randomized controlled trial","volume":"11","author":"Eftekhar","year":"2020","journal-title":"J Lasers Med Sci"},{"key":"R48-20260916","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/lsm.23346","article-title":"The fractional CO2 laser for the treatment of genitourinary syndrome of menopause: a prospective multicenter cohort study","volume":"53","author":"Li","year":"2021","journal-title":"Lasers Surg Med"},{"key":"R49-20260916","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/GME.0000000000001416","article-title":"A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET trial","volume":"27","author":"Paraiso","year":"2020","journal-title":"Menopause"},{"key":"R50-20260916","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/GME.0000000000001333","article-title":"Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial","volume":"26","author":"Politano","year":"2019","journal-title":"Menopause"},{"key":"R51-20260916","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.maturitas.2020.10.018","article-title":"Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors","volume":"144","author":"Quick","year":"2021","journal-title":"Maturitas"},{"key":"R52-20260916","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/GME.0000000000001542","article-title":"Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial","volume":"27","author":"Ruanphoo","year":"2020","journal-title":"Menopause"},{"key":"R53-20260916","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/13697137.2020.1829584","article-title":"CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial","volume":"24","author":"Salvatore","year":"2021","journal-title":"Climacteric"},{"key":"R54-20260916","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15171\/jlms.2020.11","article-title":"Effect of the fractional CO2 laser on the quality of life, general health, and genitourinary symptoms in postmenopausal women with vaginal atrophy: a prospective cohort","volume":"11","author":"Adabi","year":"2020","journal-title":"J Lasers Med Sci"},{"key":"R55-20260916","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/lsm.23247","article-title":"Fractional CO2 laser treatment of the vulva and vagina and the effect of postmenopausal duration on efficacy","volume":"53","author":"Alexiades","year":"2021","journal-title":"Lasers Surg Med"},{"key":"R56-20260916","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.maturitas.2017.07.007","article-title":"CO2-laser for the genitourinary syndrome of menopause. How many laser sessions?","volume":"104","author":"Athanasiou","year":"2017","journal-title":"Maturitas"},{"key":"R57-20260916","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/GME.0000000000001206","article-title":"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results","volume":"26","author":"Athanasiou","year":"2019","journal-title":"Menopause"},{"key":"R58-20260916","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/gyn.2016.0099","article-title":"Fractional CO2 laser treatment for vaginal atrophy and vulvar lichen sclerosus","volume":"32","author":"Baggish","year":"2016","journal-title":"J Gynecol Surg"},{"key":"R59-20260916","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10103-018-2471-3","article-title":"Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects","volume":"33","author":"Becorpi","year":"2018","journal-title":"Lasers Med Sci"},{"key":"R60-20260916","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejogrb.2017.03.036","article-title":"Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause","volume":"213","author":"Behnia-Willison","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R61-20260916","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.maturitas.2020.02.009","article-title":"Safety evaluation of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy: a prospective observational study","volume":"135","author":"Di Donato","year":"2020","journal-title":"Maturitas"},{"key":"R62-20260916","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5978\/islsm.18-OR-04","article-title":"Early effect of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy","volume":"27","author":"Eder","year":"2018","journal-title":"Laser Ther"},{"key":"R63-20260916","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5978\/islsm.28_19-OR-06","article-title":"Long-term safety and efficacy of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy","volume":"28","author":"Eder","year":"2019","journal-title":"Laser Ther"},{"key":"R64-20260916","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/GME.0000000000001428","article-title":"Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study","volume":"27","author":"Filippini","year":"2020","journal-title":"Menopause"},{"key":"R65-20260916","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/GME.0000000000001727","article-title":"The short-term efficacy and safety of fractional CO2 laser therapy for vulvovaginal symptoms in menopause, breast cancer, and lichen sclerosus","volume":"28","author":"Gardner","year":"2021","journal-title":"Menopause"},{"key":"R66-20260916","first-page":"68","article-title":"Fractional CO2 laser for treatment of vulvovaginal atrophy: a short time follow-up","volume":"14","author":"Ghanbari","year":"2020","journal-title":"J Fam Reprod Health"},{"key":"R67-20260916","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14764172.2018.1481510","article-title":"The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy","volume":"21","author":"Gittens","year":"2019","journal-title":"J Cosmet Laser Ther"},{"key":"R68-20260916","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00192-017-3352-1","article-title":"Long-term effect of thermoablative fractional CO2 laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause","volume":"29","author":"Gonzalez Isaza","year":"2018","journal-title":"Int Urogynecol J"},{"key":"R69-20260916","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.uroco.2016.10.004","article-title":"Fractional CO2 laser: a new treatment approach for stress urinary incontinence (SUI) in postmenopausal women","volume":"26","author":"Gonz\u00e1lez Isaza","year":"2017","journal-title":"Urolog\u00eda Colombiana"},{"key":"R70-20260916","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/GME.0000000000001293","article-title":"Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy","volume":"26","author":"Gordon","year":"2019","journal-title":"Menopause"},{"key":"R71-20260916","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.anplas.2020.05.002","article-title":"Carbon dioxide laser treatment for vulvovaginal atrophy in women treated for breast cancer: preliminary results of the feasibility EPIONE trial","volume":"65","author":"Hersant","year":"2020","journal-title":"Ann Chir Plast Esth\u00e9t"},{"key":"R72-20260916","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1556\/650.2019.31529","article-title":"Short-term efficacy of vaginal CO2 laser therapy as a treatment modality for genitourinary syndrome of menopause","volume":"160","author":"Kozma","year":"2019","journal-title":"Orvosi Hetilap"},{"key":"R73-20260916","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/lsm.22713","article-title":"Fractional CO2 laser of the vagina for genitourinary syndrome of menopause: is the out-of-pocket cost worth the outcome of treatment?","volume":"49","author":"Lang","year":"2017","journal-title":"Lasers Surg Med"},{"key":"R74-20260916","doi-asserted-by":"crossref","first-page":"101614","DOI":"10.1016\/j.jogoh.2019.07.010","article-title":"The results of new low dose fractional CO2 Laser\u2014a prospective clinical study in France","volume":"49","author":"Marin","year":"2020","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"R75-20260916","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/GME.0000000000000672","article-title":"Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and\/or hormonal therapy for breast cancer: a retrospective study","volume":"23","author":"Pagano","year":"2016","journal-title":"Menopause"},{"key":"R76-20260916","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/GME.0000000000001053","article-title":"Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study","volume":"25","author":"Pagano","year":"2018","journal-title":"Menopause"},{"key":"R77-20260916","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-019-05384-9","article-title":"Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study","volume":"178","author":"Pearson","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R78-20260916","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.maturitas.2014.12.006","article-title":"Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser","volume":"80","author":"Perino","year":"2015","journal-title":"Maturitas"},{"key":"R79-20260916","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00404-017-4504-8","article-title":"Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms","volume":"296","author":"Pieralli","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"R80-20260916","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00404-016-4118-6","article-title":"Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors","volume":"294","author":"Pieralli","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"R81-20260916","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s10103-017-2293-8","article-title":"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?","volume":"32","author":"Pitsouni","year":"2017","journal-title":"Lasers Med Sci"},{"key":"R82-20260916","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/GME.0000000000001738","article-title":"Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy","volume":"28","author":"Quick","year":"2021","journal-title":"Menopause"},{"key":"R83-20260916","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1016\/j.clbc.2021.01.006","article-title":"Microablative fractional CO2 laser for vulvovaginal atrophy in women with a history of breast cancer: a pilot study at 4-week follow-up","volume":"21","author":"Salvatore","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"R84-20260916","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2014.975197","article-title":"Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy","volume":"18","author":"Salvatore","year":"2015","journal-title":"Climacteric"},{"key":"R85-20260916","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/13697137.2014.899347","article-title":"A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study","volume":"17","author":"Salvatore","year":"2014","journal-title":"Climacteric"},{"key":"R86-20260916","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/asj\/sjy087","article-title":"Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women","volume":"39","author":"Samuels","year":"2019","journal-title":"Aesthet Surg J"},{"key":"R87-20260916","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/tbj.14211","article-title":"Fractional CO\u2082 vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors","volume":"27","author":"Siliquini","year":"2021","journal-title":"Breast J"},{"key":"R88-20260916","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/13697137.2017.1319815","article-title":"Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women","volume":"20","author":"Siliquini","year":"2017","journal-title":"Climacteric"},{"key":"R89-20260916","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00404-020-05868-w","article-title":"Evaluation of the efficacy of fractional CO2 laser in the treatment of vulvar and vaginal menopausal symptoms","volume":"303","author":"Sindou-Faurie","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"R90-20260916","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/lsm.23126","article-title":"The effect of fractional CO2 laser treatment on the symptoms of pelvic floor dysfunctions: pelvic floor distress inventory-20 questionnaire","volume":"51","author":"Sipos","year":"2019","journal-title":"Lasers Surg Med"},{"key":"R91-20260916","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/GME.0000000000000839","article-title":"Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes","volume":"24","author":"Sokol","year":"2017","journal-title":"Menopause"},{"key":"R92-20260916","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/lsm.23211","article-title":"The effect of vaginal microablative fractional CO2 laser treatment on vaginal cytology","volume":"52","author":"Takacs","year":"2020","journal-title":"Lasers Surg Med"},{"key":"R93-20260916","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/lsm.23066","article-title":"Efficacy of fractional CO2 laser in the treatment of genitourinary syndrome of menopause in Latin-American Population: first Peruvian experience","volume":"51","author":"Tovar-Huamani","year":"2019","journal-title":"Lasers Surg Med"},{"key":"R94-20260916","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/09513590.2019.1680625","article-title":"Ospemifene plus fractional CO2 laser: a powerful strategy to treat postmenopausal vulvar pain","volume":"36","author":"Murina","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"R95-20260916","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3109\/13697137.2015.1045485","article-title":"Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause","volume":"18","author":"Gambacciani","year":"2015","journal-title":"Climacteric"},{"key":"R96-20260916","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/lsm.22569","article-title":"Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause","volume":"49","author":"Gaspar","year":"2017","journal-title":"Lasers Surg Med"},{"key":"R97-20260916","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/GME.0000000000001353","article-title":"The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study","volume":"26","author":"Areas","year":"2019","journal-title":"Menopause"},{"key":"R98-20260916","first-page":"418","article-title":"Novel hybrid fractional erbium: YAG laser: short-term outcomes for treatment of genitourinary syndrome of menopause and dyspareunia [abstract]","volume":"175444","author":"Gueretta","year":"2017","journal-title":"IUGA Academy"},{"key":"R99-20260916","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00432-018-2614-8","article-title":"Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment","volume":"144","author":"Mothes","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"R100-20260916","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"R101-20260916","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-5122(95)00955-8","article-title":"Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women","volume":"23","author":"Bygdeman","year":"1996","journal-title":"Maturitas"},{"key":"R102-20260916","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/GME.0000000000001131","article-title":"Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial","volume":"25","author":"Diem","year":"2018","journal-title":"Menopause"},{"key":"R103-20260916","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/GME.0000000000001341","article-title":"Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women","volume":"26","author":"Mitchell","year":"2019","journal-title":"Menopause"},{"key":"R104-20260916","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"key":"R105-20260916","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0015-0282(16)56474-7","article-title":"Comparative study: Replens versus local estrogen in menopausal women","volume":"61","author":"Nachtigall","year":"1994","journal-title":"Fertil Sterility"},{"key":"R106-20260916","first-page":"346","article-title":"Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy","volume":"101","author":"Parsons","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R107-20260916","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jcp.55.6.446","article-title":"The effect of replens(R) on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry","volume":"55","author":"van der Laak","year":"2002","journal-title":"J Clin Pathol"},{"key":"R108-20260916","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors","volume":"103","author":"Davis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R109-20260916","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/GME.0000000000000613","article-title":"Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial","volume":"23","author":"Fernandes","year":"2016","journal-title":"Menopause"},{"key":"R110-20260916","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/jsm.12473","article-title":"Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial","volume":"11","author":"Fernandes","year":"2014","journal-title":"J Sex Med"},{"key":"R111-20260916","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/GME.0000000000001059","article-title":"Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study","volume":"25","author":"Fernandes","year":"2018","journal-title":"Menopause"},{"key":"R112-20260916","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"R113-20260916","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"key":"R114-20260916","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/sm2.22","article-title":"Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy","volume":"2","author":"Dahir","year":"2014","journal-title":"Sex Med"},{"key":"R115-20260916","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijgo.2010.04.023","article-title":"Effects of transdermal estradiol gel and oral tibolone on health-related quality of life after surgical menopause","volume":"110","author":"Bhattacharya","year":"2010","journal-title":"Int J Gynecol Obstet"},{"key":"R116-20260916","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-5122(96)01070-5","article-title":"Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison","volume":"26","author":"Botsis","year":"1997","journal-title":"Maturitas"},{"key":"R117-20260916","first-page":"279","article-title":"Alternative therapies in the treatment if climacteric symptoms: efficacy of tibolone vs phytoestrogens","volume":"XXXIII","author":"Caruso SF","year":"2011","journal-title":"Viorn It Ost Gin"},{"key":"R118-20260916","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1743-6109.2007.00635.x","article-title":"Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women","volume":"5","author":"Cayan","year":"2008","journal-title":"J Sex Med"},{"key":"R119-20260916","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0378-5122(95)00953-1","article-title":"Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints","volume":"23","author":"Egarter","year":"1996","journal-title":"Maturitas"},{"key":"R120-20260916","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.maturitas.2004.12.003","article-title":"Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women","volume":"52","author":"Elfituri","year":"2005","journal-title":"Maturitas"},{"key":"R121-20260916","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1471-0528.1998.tb10237.x","article-title":"A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms","volume":"105","author":"Hammar","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"R122-20260916","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1471-0528.2007.01537.x","article-title":"Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability","volume":"114","author":"Hammar","year":"2007","journal-title":"BJOG"},{"key":"R123-20260916","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0378-5122(97)00037-6","article-title":"Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users","volume":"27","author":"Hanggi","year":"1997","journal-title":"Maturitas"},{"key":"R124-20260916","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1471-0528.2002.01338.x","article-title":"Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women","volume":"109","author":"Huber","year":"2002","journal-title":"BJOG"},{"key":"R125-20260916","first-page":"117","article-title":"Efficacy and safety of oral tibolone 1.25 or 2.5 mg\/day vs. placebo in postmenopausal women","volume":"7","author":"Hudita","year":"2003","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R126-20260916","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"key":"R127-20260916","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/cmt.4.1.28.41","article-title":"The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women","volume":"4","author":"Laan","year":"2001","journal-title":"Climacteric"},{"key":"R128-20260916","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0378-5122(01)00298-5","article-title":"Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus","volume":"41","author":"Mendoza","year":"2002","journal-title":"Maturitas"},{"key":"R129-20260916","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.maturitas.2006.04.014","article-title":"Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy","volume":"55","author":"Nappi","year":"2006","journal-title":"Maturitas"},{"key":"R130-20260916","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.maturitas.2007.07.005","article-title":"Effects of tibolone and raloxifene on health-related quality of life and sexual function","volume":"58","author":"Nijland","year":"2007","journal-title":"Maturitas"},{"key":"R131-20260916","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1743-6109.2007.00726.x","article-title":"Fsd pharmacotherapy: tibolone and transdermal E2\/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial","volume":"5","author":"Nijland","year":"2008","journal-title":"J Sex Med"},{"key":"R132-20260916","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0378-5122(94)90050-7","article-title":"A study of the effect of tibolone on the vagina in postmenopausal women","volume":"18","author":"Rymer","year":"1994","journal-title":"Maturitas"},{"key":"R133-20260916","first-page":"183","article-title":"Comparing the effects of continuous hormone replacement therapy and tibolone on the genital tract of menopausal women; a randomized controlled trial","volume":"11","author":"Saeideh","year":"2010","journal-title":"J Reprod Infertil"},{"key":"R134-20260916","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0378-5122(94)00889-F","article-title":"A comparative study of two hormone replacement therapy regimens on safety and efficacy variables","volume":"21","author":"Siseles","year":"1995","journal-title":"Maturitas"},{"key":"R135-20260916","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.gme.0000247016.41007.c9","article-title":"Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study","volume":"13","author":"Swanson","year":"2006","journal-title":"Menopause"},{"key":"R136-20260916","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/cmt.4.4.314.319","article-title":"Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy","volume":"4","author":"Wu","year":"2001","journal-title":"Climacteric"},{"key":"R137-20260916","first-page":"471","article-title":"Tibolone vaginal versus per os administration in the management of post-menopausal symptoms","volume":"113","author":"Zervoudis","year":"2009","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"R138-20260916","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13697130903009195","article-title":"Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women","volume":"13","author":"Ziaei","year":"2010","journal-title":"Climacteric"},{"key":"R139-20260916","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/jsm.12125","article-title":"Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial","volume":"10","author":"Chen","year":"2013","journal-title":"J Sex Med"},{"key":"R140-20260916","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00404-010-1382-8","article-title":"The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial","volume":"283","author":"Ekin","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R141-20260916","first-page":"321","article-title":"Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort","volume":"64","author":"Grimaldi","year":"2012","journal-title":"Minerva Ginecol"},{"key":"R142-20260916","first-page":"69","article-title":"Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial","volume":"4","author":"Jokar","year":"2016","journal-title":"Int J Commu Based Nurs Midwifery"},{"key":"R143-20260916","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4236\/ijcm.2014.511084","article-title":"Oral low-molecular weight hyaluronic acid in the treatment of atrophic vaginitis","volume":"5","author":"Galia","year":"2014","journal-title":"Int J Clin Med"},{"key":"R144-20260916","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00404-010-1545-7","article-title":"The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause","volume":"283","author":"Le Donne","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R145-20260916","doi-asserted-by":"crossref","first-page":"480","DOI":"10.23736\/S2724-606X.21.04841-7","article-title":"Treatment of vulvo-vaginal atrophy with hyaluronate-based gel: a randomized controlled study","volume":"74","author":"Nappi","year":"2022","journal-title":"Minerva Obstet Gynecol"},{"key":"R146-20260916","first-page":"27","article-title":"Treatment of women with genitourinary syndrome of the menopause with application of vaginal hyaluronic acid cream","volume":"31-N.4","author":"Scala","year":"2019","journal-title":"Ital J Gynaecol Obstet"},{"key":"R147-20260916","first-page":"311","article-title":"A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors","volume":"29","author":"Carter","year":"2021","journal-title":"Support Care Cancer"},{"key":"R148-20260916","first-page":"411","article-title":"Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial","volume":"12","author":"Costantino","year":"2008","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R149-20260916","first-page":"341","article-title":"Clinical study of hyaluronic acid gel in dyspareunia caused by vaginal dryness","volume":"61","author":"Mieza Arana","year":"2018","journal-title":"Prog De Obstet Ginecol"},{"key":"R150-20260916","first-page":"4190","article-title":"Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study","volume":"20","author":"Origoni","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R155-20260916","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jogc.2017.11.040","article-title":"No. 358-intravaginal laser for genitourinary syndrome of menopause and stress urinary incontinence","volume":"40","author":"Walter","year":"2018","journal-title":"J Obstet Gynaecol Can"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:06:30Z","timestamp":1789556790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005288"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":151,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005288","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"2023-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}